Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
CytoDyn Inc CYDY
(Total Views: 586)
Posted On: 04/13/2020 8:20:26 AM
Post# of 154195
Posted By: COInvestor
Re: Longestyard #27170
Status of the 25 Patients treated under the FDA EINDs?

Has the company reported the latest status of the 12+ patients treated at Albert Einstein's Motefiore Medical center? From today's press release of the 5 Southern CA patients treated under EINDs and last weeks' reported results in New York, it seems that there is an incredible story to be told on a growing number (25) of patients treated under "Emergency Use" but I seem to have missed it...

https://finance.yahoo.com/news/southern-calif...10470.html

Patient enrollment in the Company’s two clinical trials and Emergency Investigational New Drug (EIND) is as follows:

More than 25 patients have been administered leronlimab under EINDs authorized by the U.S. Food and Drug Administration (FDA).

Rate of response in mild-to-moderate patients under EIND has been very promising with the first five patients treated being removed from oxygen.

As of last week, 12 patients have been treated in the Phase 2 trial for mild-to-moderate COVID-19 indications and, because it is a double-blinded, placebo-controlled trial, results are not yet available.

First site cleared to enroll patients in Phase 2b/3 beginning today.













(1)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site